CN1152873C - 新的二苯基哌啶衍生物 - Google Patents

新的二苯基哌啶衍生物 Download PDF

Info

Publication number
CN1152873C
CN1152873C CNB008106703A CN00810670A CN1152873C CN 1152873 C CN1152873 C CN 1152873C CN B008106703 A CNB008106703 A CN B008106703A CN 00810670 A CN00810670 A CN 00810670A CN 1152873 C CN1152873 C CN 1152873C
Authority
CN
China
Prior art keywords
methyl
phenylbenzene
piperidino
benzyl chloride
chloride base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008106703A
Other languages
English (en)
Chinese (zh)
Other versions
CN1361775A (zh
Inventor
A��J��G���Ϳ�˹��
A·J·G·巴克斯特
S·J·布罗
T·麦因纳利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Original Assignee
AstraZeneca UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca UK Ltd filed Critical AstraZeneca UK Ltd
Publication of CN1361775A publication Critical patent/CN1361775A/zh
Application granted granted Critical
Publication of CN1152873C publication Critical patent/CN1152873C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNB008106703A 1999-07-21 2000-07-18 新的二苯基哌啶衍生物 Expired - Fee Related CN1152873C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9902765A SE9902765D0 (sv) 1999-07-21 1999-07-21 Novel compounds
SE99027658 1999-07-21

Publications (2)

Publication Number Publication Date
CN1361775A CN1361775A (zh) 2002-07-31
CN1152873C true CN1152873C (zh) 2004-06-09

Family

ID=20416552

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008106703A Expired - Fee Related CN1152873C (zh) 1999-07-21 2000-07-18 新的二苯基哌啶衍生物

Country Status (17)

Country Link
US (1) US6566376B1 (cg-RX-API-DMAC10.html)
EP (1) EP1202984B1 (cg-RX-API-DMAC10.html)
JP (1) JP2003505383A (cg-RX-API-DMAC10.html)
KR (1) KR20020027498A (cg-RX-API-DMAC10.html)
CN (1) CN1152873C (cg-RX-API-DMAC10.html)
AT (1) ATE233754T1 (cg-RX-API-DMAC10.html)
AU (1) AU771344B2 (cg-RX-API-DMAC10.html)
BR (1) BR0012610A (cg-RX-API-DMAC10.html)
CA (1) CA2378084A1 (cg-RX-API-DMAC10.html)
DE (1) DE60001586T2 (cg-RX-API-DMAC10.html)
IL (1) IL147149A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA02000671A (cg-RX-API-DMAC10.html)
NO (1) NO20020282L (cg-RX-API-DMAC10.html)
NZ (1) NZ516606A (cg-RX-API-DMAC10.html)
SE (1) SE9902765D0 (cg-RX-API-DMAC10.html)
WO (1) WO2001005782A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200110540B (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
EP1962605A2 (en) * 2005-12-12 2008-09-03 Merck & Co., Inc. 2-arylthiazole derivatives as cxcr3 receptor modulators
US10344095B2 (en) * 2006-02-16 2019-07-09 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
TW200812582A (en) * 2006-04-06 2008-03-16 Astrazeneca Ab Medicaments
RU2010103104A (ru) * 2007-07-02 2011-08-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные имидазола в качестве антагонистов рецептора ccr2
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
US8778616B2 (en) 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
US9394258B2 (en) 2013-03-14 2016-07-19 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153172A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
CA2903394C (en) 2013-03-14 2021-08-31 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP3363434A1 (en) 2013-03-14 2018-08-22 Epizyme Inc Arginine methyltransferase inhibitors and uses thereof
JP2016514164A (ja) 2013-03-14 2016-05-19 エピザイム,インコーポレイティド アルギニンメチルトランスフェラーゼ阻害剤としてのピラゾール誘導体およびその使用
PT3022202T (pt) 2013-07-18 2019-09-03 Novartis Ag Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
CN108299411B (zh) * 2017-01-13 2021-02-05 中国人民解放军军事医学科学院毒物药物研究所 4,4-二苯基哌啶类化合物或其可药用盐、药物组合物及用途
US12221463B2 (en) 2020-08-07 2025-02-11 The Board Of Regents Of The University Of Oklahoma Method of promoting wound healing by inhibiting CCR3

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2139084C3 (de) 1971-08-04 1979-03-01 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen
IL90858A (en) 1988-07-07 1994-08-26 Rhone Poulenc Sante Derivatives of (AZA) naphthalensultam, their preparation and compositions containing them
US5352684A (en) 1990-04-10 1994-10-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyridines as medicaments
DE4140542A1 (de) 1991-12-09 1993-06-17 Bayer Ag Piperdylmethyl substituierte chormanderivate
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
US6339087B1 (en) 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
HN1999000149A (es) * 1998-09-09 2000-01-12 Pfizer Prod Inc Derivados de 4,4-biarilpiperidina
US6046331A (en) 1998-12-17 2000-04-04 Synaptic Pharmaceutical Corporation Imidazolones and their use in treating benign prostatic hyperplasia and other disorders

Also Published As

Publication number Publication date
CA2378084A1 (en) 2001-01-25
AU6001600A (en) 2001-02-05
EP1202984B1 (en) 2003-03-05
JP2003505383A (ja) 2003-02-12
CN1361775A (zh) 2002-07-31
SE9902765D0 (sv) 1999-07-21
IL147149A0 (en) 2002-08-14
US6566376B1 (en) 2003-05-20
ZA200110540B (en) 2003-03-24
KR20020027498A (ko) 2002-04-13
MXPA02000671A (es) 2002-07-02
NO20020282L (no) 2002-03-21
NZ516606A (en) 2003-09-26
AU771344B2 (en) 2004-03-18
NO20020282D0 (no) 2002-01-18
DE60001586D1 (de) 2003-04-10
ATE233754T1 (de) 2003-03-15
EP1202984A1 (en) 2002-05-08
DE60001586T2 (de) 2004-02-12
BR0012610A (pt) 2002-04-09
WO2001005782A1 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
CN1298715C (zh) 作为组胺h3拮抗剂的非咪唑化合物
CN1304382C (zh) 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
CN1293076C (zh) 过氧化物酶体增殖剂应答性受体δ的活化剂
CN1174978C (zh) 用作旋转异构酶抑制剂的杂环化合物
CN1243751C (zh) 用作抗变态反应药物的哌啶化合物
CN1193025C (zh) 新的1,3-二氢-2h-吲哚-2-酮衍生物,它们的制备方法以及含有它们的药物组合物
CN1361775A (zh) 新的二苯基哌啶衍生物
CN1633433A (zh) N-芳酰基环胺
CN1930143A (zh) 具有微粒体甘油三酸酯传递蛋白质抑制活性的被五元杂环取代的芳基哌啶或哌嗪
CN1229373C (zh) 作为神经激肽1拮抗剂的哌啶衍生物
CN1615300A (zh) 苯并咪唑衍生物以及它们作为gnrh拮抗剂的用途
CN1617722A (zh) 烟碱或异烟碱苯并噻唑衍生物
CN1556805A (zh) 作为nmda受体拮抗剂的哌啶衍生物
CN1642927A (zh) 环状酰胺
CN1918154A (zh) 多杂环化合物及其作为代谢型谷氨酸受体拮抗剂的用途
CN1197458A (zh) 具有磷酯酶a2抑制活性的吡咯烷衍生物
CN1659164A (zh) 苯并噁嗪酮衍生的化合物、它们的制备方法和作为药物的用途
CN1675203A (zh) 取代的1-哌嗪酰基哌啶衍生物,它们的制备方法和治疗用途
CN101065376A (zh) 2-酰胺基-4-苯基噻唑衍生物、它们的制备与治疗应用
CN1152879C (zh) 萘啶衍生物
CN1208318C (zh) 环胺ccr5受体拮抗剂
CN101035781A (zh) 2-吗啉基-4-嘧啶酮化合物
CN1921858A (zh) 哌啶基烷基氨基甲酸酯衍生物、其制备方法及其作为faah酶抑制剂的应用
CN1960727A (zh) 用作组胺-3受体的配体的萘衍生物
CN101080405A (zh) 作为m3拮抗剂的季铵盐

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee